• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe Heart Failure after Using Bortezomib in a Patient with Multiple Myeloma and Cardiac Amyloidosis of Normal Wall Thickness.

作者信息

Kao Ting-Wei, Huang Tai-Chung, Liao Che-Wei, Shun Chia-Tung, Tsai Cheng-Hsuan, Lin Yen-Hung

机构信息

Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine.

Department of Medicine, National Taiwan University Cancer Center.

出版信息

Acta Cardiol Sin. 2024 Jul;40(4):454-457. doi: 10.6515/ACS.202407_40(4).20240410A.

DOI:10.6515/ACS.202407_40(4).20240410A
PMID:39045372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261364/
Abstract
摘要

相似文献

1
Severe Heart Failure after Using Bortezomib in a Patient with Multiple Myeloma and Cardiac Amyloidosis of Normal Wall Thickness.一名患有多发性骨髓瘤和正常壁厚心脏淀粉样变性的患者使用硼替佐米后发生严重心力衰竭。
Acta Cardiol Sin. 2024 Jul;40(4):454-457. doi: 10.6515/ACS.202407_40(4).20240410A.
2
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.硼替佐米治疗多发性骨髓瘤相关心脏淀粉样变性患者，心肌功能持续改善，淀粉样沉积物持续存在。
Int J Hematol. 2010 Nov;92(4):655-8. doi: 10.1007/s12185-010-0710-x. Epub 2010 Oct 27.
3
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.硼替佐米治疗多发性骨髓瘤患者后发生严重心力衰竭：病例报告及文献复习。
Acta Haematol. 2012;128(4):244-7. doi: 10.1159/000340050. Epub 2012 Sep 4.
4
Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis.硼替佐米治疗系统性淀粉样变性患者后发生心室颤动。
Hematol Rep. 2013 Sep 16;5(3):e12. doi: 10.4081/hr.2013.e12. eCollection 2013.
5
[Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment].含硼替佐米方案对新诊断的伴有严重心脏损害的AL淀粉样变性的临床益处
Rinsho Ketsueki. 2016 Aug;57(8):987-93. doi: 10.11406/rinketsu.57.987.
6
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.硼替佐米、环磷酰胺和地塞米松治疗心脏淀粉样变性的疗效。
Intern Med J. 2022 Oct;52(10):1826-1830. doi: 10.1111/imj.15926.
7
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.硼替佐米治疗复发性 AL 淀粉样变性患者的 1 期临床试验：心脏反应和整体疗效。
QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.
8
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].[硼替佐米、地塞米松和环磷酰胺或含阿霉素方案治疗AL淀粉样变性的结果]
Vnitr Lek. 2012 Dec;58(12):896-903.
9
Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib.硼替佐米治疗系统性轻链淀粉样变患者的复发性晕厥和心脏骤停
Hematol Rep. 2016 May 10;8(2):6417. doi: 10.4081/hr.2016.6417.
10
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.一名骨髓瘤患者因蛋白酶体抑制剂硼替佐米导致急性严重心力衰竭。
Int J Hematol. 2008 Sep;88(2):219-222. doi: 10.1007/s12185-008-0139-7. Epub 2008 Jul 17.

本文引用的文献

1
2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.台湾心脏病学会2023年心脏淀粉样变诊断与治疗专家共识
Acta Cardiol Sin. 2023 Jul;39(4):511-543. doi: 10.6515/ACS.202307_39(4).20230610A.
2
Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management.心脏淀粉样变性的心律失常表现：风险分层与临床管理中的挑战
J Clin Med. 2023 Mar 29;12(7):2581. doi: 10.3390/jcm12072581.
3
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: State-of-the-Art Review.蛋白酶体抑制剂的心血管毒性：潜在机制与管理策略：最新综述
JACC CardioOncol. 2023 Feb 21;5(1):1-21. doi: 10.1016/j.jaccao.2022.12.005. eCollection 2023 Feb.
4
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
5
Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis.壁厚度正常的心脏淀粉样变性：一项回顾性分析中的患病率、临床特征及结局
Biomedicines. 2022 Jul 21;10(7):1765. doi: 10.3390/biomedicines10071765.
6
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗：欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
7
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
8
Cardiac amyloidosis without increased left ventricular wall thickness.无左心室壁增厚的心肌淀粉样变性。
Mayo Clin Proc. 2014 Jun;89(6):781-9. doi: 10.1016/j.mayocp.2014.01.013. Epub 2014 Apr 3.
9
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.硼替佐米治疗癌症相关的心脏毒性的发生率和风险：系统评价和荟萃分析。
PLoS One. 2014 Jan 29;9(1):e87671. doi: 10.1371/journal.pone.0087671. eCollection 2014.
10
Cardiotoxicity of the anticancer therapeutic agent bortezomib.硼替佐米这一抗癌治疗药物的心脏毒性。
Am J Pathol. 2010 Jun;176(6):2658-68. doi: 10.2353/ajpath.2010.090690.